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The medicinal plants were a common link between 
modern and traditional medical sciences as they were the 
main source of drugs and medicaments1. The liver is a 
vital organ of paramount importance involved in the 
maintenance of metabolic functions and detoxification 
from the exogenous and endogenous challenges, like 
xenobiotics, drugs, viral infections and chronic 
alcoholism. If during all such exposures to the above 
mentioned challenges the natural protective mechanisms 
of the liver are overpowered, the result is hepatic injury2. 
Liver diseases remain one of the serious health 
problems3. In spite of tremendous strides in the modern 
medicine, there are not much drugs available for the 
treatment of liver diseases. There are a number of 
medicinal preparations recommended in the Indian 
traditional system of medicine ‘‘Ayurveda” for the 
treatment of liver diseases. There are scientific claims to 
offer significant relief as hepatoprotective4. 
The Alocasia indica Linn. (Family- Araceae) commonly 
known as Giant Taro is a perennial herb found 
throughout greater part of India. According to ayurvedic 
literature survey, different parts of this plant are 
traditionally used in jaundice, antioxidant, analgesic, 
antiarthritic, disease of abdomen, spleen inflammation5. 
It has also reported to use in the treatment of piles6. The 
leaves juice is used as digestive, astringent, laxative, 
diuretic and rheumatic arthritis and antifungal 
properties7,8. This plant contains flavonoids, cynogenetic 
glycosides, ascorbic acid, gallic acid, mallic acid, oxalic 
acid, alocasin, amino acids, succinic acid, and ß-lectines.   
Silymarin, one of these compounds, was used as a 
standard reference and exhibited significant 
hepatoprotective and antioxidant activity against CCl4-
induced haptotoxicity in rat models9,10. Carbon 
tetrachloride accumulates in hepatic parenchyma cells 
and is metabolised to C∙Cl3 by liver cytochrome P450-
dependent monooxygenases11. One of the principal 
causes of CCl4- induced liver injury is lipid peroxidation 
induced and accelerated by free radical derivatives of 
CCl4 
12. 
The roots of Alocasia indica are used for the treatment of 
jaundice in traditional system of medicine. However, 
there is lack of scientific report regarding the 
hepatoprotective activity of Alocasia indica. The present 
investigation is an endeavor to validate the scientific use 
of hydro-ethanolic extract of the Alocasia indica (AI-E) 
against carbon tetrachloride induced hepatic damage in 
experimental animals. 
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ABSTRACT: 
The hepatoprotective activity of hydro-alcohol extract of roots of Alocasia indica Linn. (AI-E) was evaluated against carbon 
tetrachloride (CCl4) induced hepatic damage in rats. The AI-E at dose of 400 mg/kg is administered orally once daily for 
fourteen days. The substantially elevated serum enzymatic levels of serum glutamate oxaloacetate transaminase (AST), 
glutamate pyruvate transaminase (ALT), alkaline phosphatase (ALP), total lipoprotein (TP), total cholesterol (TC), triglyceride 
(TG), albumin (ALB), hepatic malondialdehyde (MDA) content, superoxide dismutase (SOD), hyaluronic acid (HA)  and liver 
index were restored towards normalization significantly by the AI-E at dose of 400 mg/kg. AI-E 400mg/kg dose exhibited 
significant hepatoprotective activity against carbon tetrachloride induced hepatotoxicity in rats. The biochemical observations 
were supplemented with histopathological examination of rat liver sections. The results of this study strongly indicate that roots 
of Alocasia indica have potent hepatoprotective activity against carbon tetrachloride induced hepatic damage in experimental 
animals. This study suggests that possible mechanism of this activity may be due to the presence of flavonoids and phenolics 
compound in the AI-E which may be responsible to hepatoprotective activity. 
Keyword: Hepatoprotective, Alocasia indica, Carbon tetrachloride, Roots. 
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MATERIALS AND METHODS 
Plant material 
The fresh roots of Alocasia indica Linn. used in the 
present study were collected from local areas of 
Ibrahimpatnam, Hyderabad, India in the month of 
February (winter) 2013. The plant species was 
authenticated by Prof. B. Amarendhar Reddy, M.sc 
(Botany), Sai Gouthami College, Ibrahimpatnam, R.R. 
District, India and the voucher herbarium specimen was 
deposited in the institute’s herbarium. The fresh roots of 
Alocasia indica Linn. were separated from plant, washed 
under running tap water and then with isopropyl alcohol 
(5%) followed by distilled water. Roots were cut into 
small pieces and allowed it to shed dry (temperature 
300C, relative humidity 45 -55%) for 15 days and then 
homogenized to get a coarse powder. This powder was 
stored in an air tight container and used for further 
successive extraction. 
Preparation of Extract: Hydro-alcoholic extract (by 
cold maceration method)  
About 250 g of the powder was extracted with hydro-
alcohol (ethanol- 95% and water in 1:1 proportion) at 
room temperature by cold maceration method13. The 
filtrate was collected and concentrated on heating mantle 
at 45°C till a syrupy mass was obtained. Then the extract 
was again dried by using rotary evaporator under 
controlled condition of temperature and pressure. The 
extract thus obtained was preserved at - 4°C. The 
percentage yield was found to be 6.14 g. 
Chemicals 
Silymarin was used as the reference drug (positive 
control); carbon tetrachloride (CCl4), purchased from 
Merck Specialities Pvt. Ltd. Mumbai, (India); total 
cholesterol (TC), triglyceride (TG), total lipoprotein 
(TP), serum albumin (SA), alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), alkaline 
phosphatase (ALP), hepatic malondialdehyde (MDA), 
and superoxide dismutase (SOD) commercial assay kits 
were purchased from Erba Diagonostics Mannheim 
GmbH, Mumbai, (India); total hyaluronic acid (HA), 
obtained from Span Diagnostics Ltd. Mumbai (India), all 
kits were for animals; all chemicals and reagents, unless 
specified otherwise, were of analytical grade and were 
not purified, dried or pretreated, and purchased from 
commercial sources. 
Animals and Experimental procedure: 
Male Wistar rats (10 weeks old, 250-300g) were 
obtained from animal centre of Pretox Research Centre, 
Sachin, Surat, Gujarat, India. The rats were housed in 
plastic cages under identical conditions (12/ 12 h light 
/dark cycle), in environmentally controlled rooms 
(22±30C temperature, 50±20% relative humidity), 
including free access to both food (standard rat chow) 
and tap water. Animal care and treatment were 
conducted in compliance with Committee for the 
Purpose of Control and Supervision on Experiments on 
Animals (CPCSEA) guidelines. The experimental 
protocol was approved by the institutional animal ethics 
committee (IAEC protocol no.PRC/AFC/2012/26) of 
Pretox Research Centre, Sachin, Surat, Gujarat, India  
They were allowed for acclimation under climate-
controlled conditions for a week before use. We 
compared survival in all groups throughout the 
treatment. All animals were carefully monitored, and the 
number of dead rats was recorded every day. 
Acute toxicity study: 
Acute toxicity study was carried out according to the 
Organization of Economic Co-operation and 
Development (OECD) guideline for testing of chemicals, 
TG42514, 10 female Wister rats were randomly divided 
into two groups of five animals. The AI-E at a single 
dose of 2000mg/kg body weight was given orally to one 
at a time, at a minimum of 48-hour intervals in test 
group, if the animal dies; conduct the main test to 
determine the LD50.  If the animal survives, dose four 
additional animals sequentially so that a total of five 
animals are tested. However, if three animals die, the 
limit test is terminated and the main test is performed. 
The LD50 is greater than 2000mg/kg if three or more 
animals survive. The control group received vehicle. 
Body weight, signs of toxicity and mortality were 
observed after the administration at the first, second, 
fourth and sixth hour and once daily for 14 days. On the 
day 15, all rats were fasted for 12-16h, and then 
sacrificed by an intraperitoneal injection (Overdose 
60mg/kg) Ketamine hydrochloride for necropsy 
examination. The internal organs were excised and 
weighed. The gross pathological observations of the 
tissues were performed.  
Animal model and drug treatment: 
The rats were treated by subcutaneous injection of CCl4 
(with an initial dose of 4 ml/kg followed by 30 ml/kg 
doses) twice a week (40%, diluted in olive oil) for 14 
weeks (from the end of tenth-week, 2 rats were selected 
every week for pathological observation, until model 
control rats were established) with the exception of 
normal control group which were treated with olive oil 
only15. Rats were randomly divided into four groups (n = 
10): (a) normal control rats receiving distilled water, (b) 
CCl4 rats receiving distilled water, (c) CCl4 rats receiving 
Silymarin (100 mg/kg, mixed with distilled water),2 and 
(d) CCl4 rats receiving AI-E (400mg/kg), each given by 
gavages once daily for 8 weeks starting from the 14 
week onset of CCl4 treatment rats. The model control 
group and the normal control group were given equal 
volume of distilled water. The rats were killed; liver in 
fasted status (12-16h) after 22 weeks. The liver was 
immediately removed and weighed after blood was 
collected from the abdominal aorta. Liver samples were 
fixed in neutralized formalin for pathological 
examination. Blood samples were centrifuged at 3000 
rpm for 10 min at 40C to obtain blood serum. 
Measurement of liver and biochemical assay: 
Liver index were calculated as liver weight divided by 
body weight. The activities of AST, ALT, and ALP the 
contents of HA, TC, TG, TP, ALB the levels of MDA 
and SOD, were determined using analysis kits. 
Histopathological observations: 
The liver specimens were fixed with 10% neutral 
formalin and embedded in paraffin. The paraffin 
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embedded liver tissues were sliced into 4 µm pieces and 
stained with Hematoxylin–Eosin (H-E) and Masson–
Trichrome (M-T), respectively, for photomicroscopic 
assessment. A numerical scoring system for 
histologically assessing the extent of fibrosis was 
adapted from the formula of Scheuer16, with minor 
modification8.  
Briefly, fibrosis was staged as:  
Stage 0: no fibrosis; Stage 1: enlarged, fibrous portal 
tracts; Stage 2: periportal or portal-portal septa, but intact 
architecture; Stage 3: fibrosis with architectural 
distortion; stage 4: probable or definite cirrhosis.  
Additionally, hepatocyte necrosis or degeneration 
severity was also graded as:  
Grade 0: no hepatocyte necrosis or degeneration; Grade 
1: focal necrosis or degeneration of hepatocytes (mild, 
lesion <3); Grade 2: multifocal necrosis or degeneration 
of hepatocytes (moderate, lesion >3); Grade 3, locally 
extensive or diffuse necrosis or degeneration of 
hepatocytes (severe). The liver scoring examination was 
performed by a pathologist who was blinded to rats’ 
treatment assignment. Fibrosis and hepatocyte scores 
were given after the pathologist had examined 
throughout three different areas in the tissue slide for 
each rat. 
STATISTICAL ANALYSIS 
All values were expressed as the means ±S.E.M. 
(standard error of means). Significant differences 
between the groups were statistically analyzed using an 
one-way analysis of variance (ANOVA), followed by 
Tukey's Multiple Comparison Test, while liver 
histopathologic examination data was evaluated using 
SPSS 17.0 package, P < 0.01 and < 0.001 considered 
statistically significant. 
RESULTS 
Acute toxicity study of AI-E: 
In the acute toxicity study, the behavioural signs of 
toxicity observed in the rats at 2000 mg extract/kg body 
weight were rubbing of nose and mouth on the floor of 
the cage and restlessness. Gross pathological study 
showed no abnormality in all the organs examined. 
Absence of death in test dose group showed that the LD50 
of the AI-roots extract is greater than 2000 mg extract/ 
kg body weight. 
Protective effects of AI-E on serum index of CCl4-
injured liver fibrotic rats: 
The activities of AST, ALT and ALP in serum were 
significantly reduced by AI-E, the contents of MDA and 
HA in serum were significantly reduced by AI-E, and 
meanwhile the levels of TP and ALB in serum were also 
increased by AI-E. The activities of ALT, the contents of 
HA and TC in serum were significantly reduced by 
Silymarin, and meanwhile the levels of TP and SOD in 
serum were also increased by Silymarin (Table 1).
 
Table 1: Effects of AI-E on serum index in CCl4 injured liver fibrotic rats. 
                  Normal                                    CCl4                                                     Silymarin                   AI-E 
AST  144.73 ± 7.86  394.92 ± 16.40###  186.87 ± 9.27###*** 197.43± 11.52###*** 
ALT  56.33 ± 2.09  282.85 ± 6.04###  67.26 ± 7.99###***  59.64 ± 5.19*** 
ALP  147.66±9.57  268±17.23###  164±13.75***  159±14.86*** 
TP  6.59 ± 0.19  3.27 ± 0.21###  5.49 ± 0.14###***  5.26 ± 0.22###*** 
TC  85.73 ± 1.71  159.36 ± 3.91###  90.66 ± 2.80##***  105.28 ± 2.80###*** 
ALB  3.58 ± 0.10  2.65 ± 0.11###  3.41 ± 0.08##***  3.33 ± 0.09###*** 
MDA  1.69 ± 0.03  2.97 ± 0.13###  2.18 ± 0.09###***  1.57 ± 0.07#*** 
SOD  93.60 ± 0.45  92.70 ± 0.37  93.1 ± 1.39  95.30 ± 1.54#*** 
HA  54.30 ± 2.51  87.20 ± 1.83###  63.30 ± 2.51###***  51.40 ± 2.79** 
LI  3.35 ± 0.08  3.88 ± 0.05###  3.52 ± 0.06###***  3.39 ± 0.05*** 
LV 3.56 ± 0.08  4.02 ± 0.08###  3.74 ± 0.04###***  3.43 ± 0.05###*** 
# Represents statistical significance vs. Normal control. 
* Represents statistical significance vs. CCl4. 
**P < 0.01, ***P < 0.001 
#P<0.05, ## P<0.01, ###P<0.001.  
 
Effect of AI-E on liver homogenate index: 
Results showed that liver AST activities and MDA 
production were obviously decreased by AI-E (400 
mg/kg) treatment (P < 0.01), liver ALT production and 
the content of TC (P < 0.001) were markedly decreased 
by AI-E (400 mg/kg) treatment as compared with model 
control group. Whereas liver SOD, TG activity and LI 
were no significant difference when compared with 
model control group (Table 2). 
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Table 2: Effects of AI-E on liver indicators in CCl4 injured liver fibrotic rats. 
                              Normal                             CCl4                                           Silymarin                         AI-E 
AST   44.07 ± 5.67  78.01 ± 6.19###  55.11 ± 4.68###***    58.38 ± 6.81** 
ALT  32.10 ± 7.34  44.83 ± 5.46###  25.18 ± 5.87***       20.39 ± 5.15###*** 
TC  85.73 ± 1.71  159.36 ± 3.91###  90.66 ± 2.80##***    105.28 ± 2.80###*** 
TG  0.12± 0.03  0.27±0.07###  0.26±0.07###                0.24±0.07### 
MDA  8.77 ± 1.45  10.28 ± 2.82  8.88 ± 1.34                6.96 ± 1.13** 
SOD  11.49 ± 0.87  11.16 ± 0.79  11.19 ± 0.64                12.16 ± 1.54 
LI  2.14 ± 0.06  3.21 ± 0.07###  2.86 ± 0.06###***        3.26 ± 0.06### 
# Represents statistical significance vs. Normal control.              * Represents statistical significance vs. CCl4. 
**P < 0.01, ***P < 0.001          ## P<0.01, ###P<0.001. 
Effects of AI-E on pathological examination 
Liver histopathological examination showed no 
histological abnormalities in normal control liver, portal 
areas were clear, the hepatic lobular architecture was 
normal, did not see connective tissue proliferation (Fig. 
1A and B); liver tissue in untreated CCl4 injured rats had 
more steatosis, cell necrosis and inflammatory 
infiltration than those in normal control rats. Histological 
abnormalities in model rat livers also showed apparent 
formation of fibrotic septa, encompassing regenerated 
hepatocytes into pseudolobules, the surface of liver was 
unsmooth, lobular structure was damaged, and 
accompanied by higher collagen content in the liver, 
which fulfilled the diagnostic standard for chronic 
hepatitis ( Fig. 1C and D); AI-E (400 mg/kg) treatment 
markedly alleviated the degree of liver fibrosis and 
significantly lowered collagen deposited ( Table 3 and 
Fig. 1E and F). 
 
 
Figure 1: Histological image of liver tissues. The normal lobular architecture with central veins and radiating hepatic 
cords in normal control rat (A and B). Fatty degeneration, necrosis,  infiltration of inflammatory cells and apparent 
formation of fibrotic septa in the CCl4 model rat (C and D). The degree of liver damage and fibrosis were significantly 
reduced in the AI-E (400 mg/kg) treatment rat (E and F). Magnification of microscope is 200X. 
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Table 3: Effects of AI-E on the pathological grading of CCl4 injured liver fibrotic rats. 
Group                       Animal number           Normal                       Mild           Moderate       Severe        P 
Normal   10        10            0               0            0  
CCL4   10         0            0               5         6 
Silymarin  10         0            4               4         0         0.002 
AI-E   10         0            4               4         0         0.002 
The P values were compared with CCL4 treatment group. 
 
DISCUSSION AND CONCLUSION 
In this present study, AI-E was evaluated for the 
hepatoprotective activity using CCl4 induced 
hepatotoxicity in rat. CCl4 is being used extensively to 
investigate hepatoprotective activity on various 
experimental animals17,18. The changes associated with 
CCl4 induced liver damage are similar to that of acute 
viral hepatitis, due to preferred as the experimental 
model19,20. The ability of a hepatoprotective drug to 
reduce the injurious effects or to preserve the normal 
hepatic physiological mechanisms that have been 
disturbed by a hepatotoxin is the index of its protective 
effects21. The hepatotoxicity induced by CCl4 is due to its 
metabolite CCl3, a free radical that alkylates cellular 
proteins and other macromolecules with a simultaneous 
attack on polyunsaturated fatty acids, in the presence of 
oxygen, to produce lipid peroxides, leading to liver 
damage22. Hepatocellular necrosis leads to elevation of 
the serum marker enzymes, which are released from the 
liver into blood23. The increased levels of AST, ALT, 
ALP and serum bilirubin are conventional indicators of 
liver injury24,25. 
Many cases it was found that oxidative damage is a 
substrate for hepatic fibrogenesis. Oxidative stress has 
been considered as a major molecular mechanism 
involved in CCl4toxicity
26. Previous reports have shown 
that oxidative stresses play an important role for the 
inactivation of Kupffer cells in the initial CCl4-induced 
rat liver fibrosis27,28. 
Hepatic fibrosis is usually initiated by hepatocyte 
damage. Biologic factors (such as hepatitis virus, bile 
duct obstruction, cholesterol overload, schistosomiasis, 
etc.) or chemical factors (such as CCl4 administration, 
alcohol intake, etc.) were known to contribute to liver 
fibrosis. The incidence of chronic fibrosis is high, but 
there have been no satisfactory agents with ascertained 
effectiveness and few side effects. So, finding effective 
ways to inhibit liver fibrosis and prevent the 
development of cirrhosis are of great significance. 
In this study, CCl4-induced liver fibrosis model was 
established to investigate the anti-fibrotic effects of AI-E 
in vivo. The results have shown that the rats receiving 
CCl4 caused a significant elevation of liver index, serum 
ALT, AST, and HA, while after treatment with AI-E 
these indexes were markedly reduced. Moreover, the 
degrees of pathological changes followed chronic 
intoxication with CCl4 which were also ameliorated 
remarkably by AI-E treatment, indicating AI-E have 
positive antifibrotic effects. 
In this present study, CCl4-induced increased serum AST 
and ALT were significantly suppressed by treating with 
AI-E. In chronic liver diseases such as alcoholic 
hepatitis, hepatic fibrosis, hepatic cirrhosis, the serum 
ALB and TP levels were reduced due to protein synthesis 
disorder in hepatocytes29. As Table 1 showed, treatment 
with AI-E elevated the ALB and TP levels revealed the 
ability of enhancement of liver cells regeneration. 
In conclusions, the hydro-alcoholic extracts of root of 
Alocasia indica Linn. exhibited protective effect against 
CCl4-induced hepatotoxicity and possess antifibrotic 
activities. The result supports the use of the plant as 
described in folk medicine, that the root of plant can be 
used to treat liver and gastric disorders. Further studies 
are required to isolate the active constituents involved in 
the antifibrotic and hepatoprotective activity of the plant. 
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